Solasia Pharma K.K. (4597.T)
JPY 42.0
(2.44%)
JPY 42.0
(2.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.47 Billion JPY | -68.85% |
| 2022 | 3.13 Billion JPY | 12.17% |
| 2021 | 2.79 Billion JPY | -35.94% |
| 2020 | 4.36 Billion JPY | 45.04% |
| 2019 | 3 Billion JPY | 19.1% |
| 2018 | 2.52 Billion JPY | 77.68% |
| 2017 | 1.42 Billion JPY | 47.39% |
| 2016 | 963.79 Million JPY | 3.42% |
| 2015 | 931.88 Million JPY | 30.52% |
| 2014 | 713.96 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 215 Million JPY | -8.9% |
| 2024 Q2 | 271 Million JPY | 26.05% |
| 2023 Q4 | 236 Million JPY | -35.52% |
| 2023 Q1 | 373 Million JPY | -55.01% |
| 2023 Q2 | 378 Million JPY | 1.34% |
| 2023 Q3 | 366 Million JPY | -3.17% |
| 2023 FY | 976 Million JPY | -68.85% |
| 2022 Q3 | 947 Million JPY | 40.71% |
| 2022 Q1 | 682 Million JPY | 12.91% |
| 2022 FY | 3.13 Billion JPY | 12.17% |
| 2022 Q4 | 829 Million JPY | -12.46% |
| 2022 Q2 | 673 Million JPY | -1.32% |
| 2021 Q3 | 706 Million JPY | -10.63% |
| 2021 FY | 2.79 Billion JPY | -35.94% |
| 2021 Q1 | 692 Million JPY | -69.54% |
| 2021 Q2 | 790 Million JPY | 14.16% |
| 2021 Q4 | 604 Million JPY | -14.45% |
| 2020 Q2 | 796 Million JPY | 23.22% |
| 2020 Q3 | 643 Million JPY | -19.22% |
| 2020 FY | 4.36 Billion JPY | 45.04% |
| 2020 Q1 | 646 Million JPY | -45.11% |
| 2020 Q4 | 2.27 Billion JPY | 253.34% |
| 2019 Q3 | 707 Million JPY | 25.13% |
| 2019 Q1 | 554 Million JPY | -41.56% |
| 2019 FY | 3 Billion JPY | 19.1% |
| 2019 Q4 | 1.17 Billion JPY | 66.48% |
| 2019 Q2 | 565 Million JPY | 1.99% |
| 2018 Q4 | 948 Million JPY | 48.13% |
| 2018 Q3 | 640 Million JPY | 5.09% |
| 2018 Q2 | 609 Million JPY | 87.38% |
| 2018 Q1 | 325 Million JPY | -44.59% |
| 2018 FY | 2.52 Billion JPY | 77.68% |
| 2017 Q1 | 246.91 Million JPY | -19.45% |
| 2017 Q2 | 311.81 Million JPY | 26.29% |
| 2017 Q3 | 275.24 Million JPY | -11.73% |
| 2017 FY | 1.42 Billion JPY | 47.39% |
| 2017 Q4 | 586.56 Million JPY | 113.11% |
| 2016 Q4 | 306.52 Million JPY | 52.05% |
| 2016 FY | 963.79 Million JPY | 3.42% |
| 2016 Q3 | 201.59 Million JPY | 0.47% |
| 2016 Q2 | 200.65 Million JPY | -21.32% |
| 2016 Q1 | 255.01 Million JPY | -6.38% |
| 2015 Q3 | 213.48 Million JPY | 0.0% |
| 2015 Q4 | 272.38 Million JPY | 27.59% |
| 2015 FY | 931.88 Million JPY | 30.52% |
| 2014 FY | 713.96 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 96.618% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.944% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.728% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 99.253% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 60.496% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 97.751% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 94.915% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.723% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 72.056% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 97.757% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 96.81% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 87.224% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 82.07% |
| Tsumura & Co. | 48.8 Billion JPY | 96.975% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 95.571% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 92.445% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 97.684% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 88.338% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 96.352% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 96.749% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 64.494% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 75.172% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 71.739% |
| MedRx Co., Ltd | 959 Million JPY | -53.91% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | 48.638% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | 37.739% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 93.892% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 95.834% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -100.767% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 98.521% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | 34.612% |